Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Total Debt (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Total Debt data on record, last reported at $379.0 million in Q4 2025.

  • For Q4 2025, Total Debt changed 0.14% year-over-year to $379.0 million; the TTM value through Dec 2025 reached $379.0 million, changed 0.14%, while the annual FY2025 figure was $379.0 million, 0.14% changed from the prior year.
  • Total Debt reached $379.0 million in Q4 2025 per CAI's latest filing, up from $376.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $379.5 million in Q4 2024 and bottomed at $373.7 million in Q2 2025.